{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:51:48Z","timestamp":1790459508250,"version":"4.1.0"},"reference-count":217,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI110557"],"award-info":[{"award-number":["UM1-AI110557"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS080821"],"award-info":[{"award-number":["R01-NS080821"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Kirschstein-NRSA 2T32HD007505-21"],"award-info":[{"award-number":["Kirschstein-NRSA 2T32HD007505-21"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00138","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T23:31:45Z","timestamp":1517527905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird\u2019s Eye View"],"prefix":"10.3389","volume":"9","author":[{"given":"Elizabeth A.","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"B1","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin\u2019s disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"key":"B2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13365-012-0080-7","article-title":"Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies","volume":"18","author":"Bellizzi","year":"2012","journal-title":"J Neurovirol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J Investig Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jns.2015.04.010","article-title":"Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis","volume":"353","author":"Asztely","year":"2015","journal-title":"J Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1212\/NXI.0000000000000123","article-title":"Hematologic modifications in natalizumab-treated multiple sclerosis patients: an 18-month longitudinal study","volume":"2","author":"Bridel","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315596994","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J Neurovirol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","article-title":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese multiple sclerosis population","volume":"45","author":"Correia","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517728814","article-title":"Anti-JCV serology during natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters","author":"Schwab","year":"2017","journal-title":"Mult Scler"},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756285612450936","article-title":"Current and emerging therapies in multiple sclerosis: a systematic review","volume":"5","author":"Castro-Borrero","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"963748","DOI":"10.1155\/2013\/963748","article-title":"Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis","volume":"2013","author":"Buc","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1720827","DOI":"10.1155\/2016\/1720827","article-title":"Regulatory T cells: molecular actions on effector cells in immune regulation","volume":"2016","author":"Arce-Sillas","year":"2016","journal-title":"J Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molmed.2009.12.003","article-title":"Disturbed regulatory T cell homeostasis in multiple sclerosis","volume":"16","author":"Venken","year":"2010","journal-title":"Trends Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e21386","DOI":"10.1371\/journal.pone.0021386","article-title":"T regulatory cells are markers of disease activity in multiple sclerosis patients","volume":"6","author":"Dalla Libera","year":"2011","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4049\/jimmunol.1500759","article-title":"Circulating follicular regulatory T cells are defective in multiple sclerosis","volume":"195","author":"Dhaeze","year":"2015","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00878525","article-title":"Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?","volume":"243","author":"Salmaggi","year":"1996","journal-title":"J Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.177561\/jnen.2016-006","article-title":"Cytokines in multiple sclerosis \u2013 possible targets for immune therapies","volume":"1","author":"Trenova","year":"2016","journal-title":"J Neurol Exp Neurosci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6104054","DOI":"10.1155\/2017\/6104054","article-title":"IL-10: a multifunctional cytokine in viral infections","volume":"2017","author":"Rojas","year":"2017","journal-title":"J Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1128\/JVI.01098-09","article-title":"Virus-encoded homologs of cellular interleukin-10 and their control of host immune function","volume":"83","author":"Slobedman","year":"2009","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.4049\/jimmunol.1103139","article-title":"IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection","volume":"189","author":"Das","year":"2012","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9657","DOI":"10.1128\/JVI.76.19.9657-9663.2002","article-title":"Susceptibility to polyomavirus-induced tumors in inbred mice: role of innate immune responses","volume":"76","author":"Velupillai","year":"2002","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ana.1004","article-title":"Cellular and humoral immune response in progressive multifocal leukoencephalopathy","volume":"49","author":"Weber","year":"2001","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T Cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog"},{"key":"B34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","volume":"47","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","article-title":"Increased program cell death\u20131 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy","volume":"60","author":"Tan","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ana.20514","article-title":"A PD-1 polymorphism is associated with disease progression in multiple sclerosis","volume":"58","author":"Kroner","year":"2005","journal-title":"Ann Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jneuroim.2017.02.006","article-title":"PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS","volume":"305","author":"Pawlak-Adamska","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.4049\/jimmunol.176.2.1148","article-title":"Polyoma virus-like particles elicit polarized cytokine responses in APCs from tumor-susceptible and -resistant mice","volume":"176","author":"Velupillai","year":"2006","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12026-014-8496-1","article-title":"The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease","volume":"58","author":"Hatton","year":"2014","journal-title":"Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1086\/653823","article-title":"Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier","volume":"202","author":"Chapagain","year":"2010","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1099\/vir.0.023184-0","article-title":"Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter\/enhancer of JC virus and supports viral activity","volume":"91","author":"Marshall","year":"2010","journal-title":"J Gen Virol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"197807","DOI":"10.1155\/2013\/197807","article-title":"Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy","volume":"2013","author":"Johnson","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/infdis\/jiv755","article-title":"Opportunistic DNA recombination with Epstein-Barr virus at sites of control region rearrangements mediating JC virus neurovirulence","volume":"213","author":"Wortman","year":"2016","journal-title":"J Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1074-7613(00)80040-0","article-title":"PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction","volume":"10","author":"Garrett-Sinha","year":"1999","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","article-title":"Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients","volume":"194","author":"Lindberg","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1128\/JVI.03221-13","article-title":"Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy","volume":"88","author":"Marshall","year":"2014","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1086\/653824","article-title":"The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology?","volume":"202","author":"Houff","year":"2010","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1212\/nxi.0000000000000292","article-title":"Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells","volume":"3","author":"Saraste","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab: a new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-\u03b14-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int Immunol"},{"key":"B56","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4049\/jimmunol.137.4.1270","article-title":"A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1","volume":"137","author":"Rothlein","year":"1986","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e40443","DOI":"10.1371\/journal.pone.0040443","article-title":"Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS","volume":"7","author":"Flanagan","year":"2012","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/brain\/123.6.1092","article-title":"Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment","volume":"123","author":"Carrithers","year":"2000","journal-title":"Brain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ni.1716","article-title":"C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE","volume":"10","author":"Reboldi","year":"2009","journal-title":"Nat Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.4049\/jimmunol.181.12.8391","article-title":"CCR6 regulates the migration of inflammatory and regulatory T cells","volume":"181","author":"Yamazaki","year":"2008","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1084\/jem.20110434","article-title":"Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE","volume":"208","author":"Rothhammer","year":"2011","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jaci.2016.11.045","article-title":"Recognition of viral and self-antigens by TH1 and TH1\/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses","volume":"140","author":"Paroni","year":"2017","journal-title":"J Allergy ClinImmunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood-brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1742-2094-9-245","article-title":"Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation","volume":"9","author":"Sagar","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.4049\/jimmunol.165.8.4338","article-title":"Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells","volume":"165","author":"Puig-Kroger","year":"2000","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","article-title":"Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis","volume":"7","author":"de Andres","year":"2012","journal-title":"PLoS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4049\/jimmunol.171.2.745","article-title":"CD49d overexpression and T cell autoimmunity","volume":"171","author":"Mo","year":"2003","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e47578","DOI":"10.1371\/journal.pone.0047578","article-title":"Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis","volume":"7","author":"Bornsen","year":"2012","journal-title":"PLoS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e81685","DOI":"10.1371\/journal.pone.0081685","article-title":"Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients","volume":"8","author":"Mellerg\u00e5rd","year":"2013","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1468-1331.2007.02037.x","article-title":"Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis","volume":"15","author":"Khademi","year":"2008","journal-title":"Eur J Neurol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivisakk","year":"2009","journal-title":"Neurology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/1352458510392263","article-title":"CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment","volume":"17","author":"Frisullo","year":"2011","journal-title":"Mult Scler"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1212\/NXI.0000000000000210","article-title":"Disrupted balance of T cells under natalizumab treatment in multiple sclerosis","volume":"3","author":"Kimura","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B75","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.it.2017.04.006","article-title":"The enigmatic role of viruses in multiple sclerosis: molecular mimicry or disturbed immune surveillance?","volume":"38","author":"Geginat","year":"2017","journal-title":"Trends Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ane.12080","article-title":"Immune cells after prolonged natalizumab therapy: implications for effectiveness and safety","volume":"128","author":"Marousi","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"B77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","article-title":"CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients","volume":"309","author":"Carotenuto","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann Neurol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2014","journal-title":"Mult Scler"},{"key":"B81","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/cei.12590","article-title":"High interindividual variability in the CD4\/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis","volume":"180","author":"Harrer","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1084\/jem.20140540","article-title":"VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells","volume":"211","author":"Schneider-Hohendorf","year":"2014","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1352458509355068","article-title":"Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid","volume":"16","author":"Mellergard","year":"2010","journal-title":"Mult Scler"},{"key":"B84","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","article-title":"The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers","volume":"16","author":"Khademi","year":"2009","journal-title":"Eur J Neurol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"key":"B86","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/jvi.02506-10","article-title":"Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome","volume":"85","author":"Gheuens","year":"2011","journal-title":"J Virol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J Virol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.4049\/jimmunol.1003812","article-title":"Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus","volume":"186","author":"Molloy","year":"2011","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.4049\/jimmunol.1102104","article-title":"Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think","volume":"187","author":"McDermott","year":"2011","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12974-015-0460-z","article-title":"Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation","volume":"12","author":"Mazzola","year":"2015","journal-title":"J Neuroinflammation"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1155\/2014\/307872","article-title":"PML-IRIS during fingolimod diagnosed after natalizumab discontinuation","volume":"2014","author":"Killestein","year":"2014","journal-title":"Case Rep Neurol Med"},{"key":"B96","volume-title":"Internal Data File","year":"2016"},{"key":"B97","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jneuroim.2014.01.008","article-title":"Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis","volume":"268","author":"Sato","year":"2014","journal-title":"J Neuroimmunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e111115","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PLoS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1177\/1352458514523496","article-title":"Differential effects of fingolimod on B-cell populations in multiple sclerosis","volume":"20","author":"Nakamura","year":"2014","journal-title":"Mult Scler"},{"key":"B100","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acn3.155","article-title":"Fingolimod treatment promotes regulatory phenotype and function of B cells","volume":"2","author":"Gr\u00fctzke","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaut.2016.03.012","article-title":"Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with multiple sclerosis","volume":"70","author":"Blumenfeld","year":"2016","journal-title":"J Autoimmun"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s11481-013-9465-5","article-title":"Fingolimod modulates peripheral effector and regulatory T cells in MS patients","volume":"8","author":"Serpero","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5114\/ceji.2015.54599","article-title":"Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients \u2013 preliminary study","volume":"40","author":"Rudnicka","year":"2015","journal-title":"Cent Eur J Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e113025","DOI":"10.1371\/journal.pone.0113025","article-title":"Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients","volume":"9","author":"Muls","year":"2014","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/1352458513481395","article-title":"Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy","volume":"19","author":"Yokoseki","year":"2013","journal-title":"Mult Scler"},{"key":"B107","unstructured":"Gilenya (Novartis Pharmaceuticals Corporation): FDA Package Insert2016"},{"key":"B108","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1212\/NXI.0000000000000209","article-title":"The VZV\/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients","volume":"3","author":"Mathias","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B110","volume-title":"Updated Recommendations to Minimise the Risk of the Rare Brain Infection PML with Tecfidera","year":"2015"},{"key":"B111","unstructured":"Tecfidera (Biogen Inc.): FDA Package Insert2017"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1212\/nxi.0000000000000274","article-title":"Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate","volume":"3","author":"Baharnoori","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B114","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","article-title":"PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter?","volume":"87","author":"Lehmann-Horn","year":"2016","journal-title":"Neurology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","article-title":"Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases","volume":"264","author":"Gieselbach","year":"2017","journal-title":"J Neurol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMc1413724","article-title":"PML in a patient without severe lymphocytopenia receiving dimethyl fumarate","volume":"372","author":"Nieuwkamp","year":"2015","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fimmu.2016.00278","article-title":"Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases","volume":"7","author":"Al-Jaderi","year":"2016","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","article-title":"Dimethylfumarate is a potent inducer of apoptosis in human T cells","volume":"121","author":"Treumer","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1586\/14737175.8.11.1683","article-title":"Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies","volume":"8","author":"Linker","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"B120","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02400.x","article-title":"The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network","volume":"139","author":"Ockenfels","year":"1998","journal-title":"Br J Dermatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1212\/nxi.0000000000000076","article-title":"Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1352458515608961","article-title":"Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients","volume":"22","author":"Longbrake","year":"2015","journal-title":"Mult Scler"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","article-title":"Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","article-title":"Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients","volume":"198","author":"Wu","year":"2017","journal-title":"J Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1212\/NXI.0000000000000211","article-title":"Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets","volume":"3","author":"Lundy","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B126","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1601649","article-title":"Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis","volume":"198","author":"Li","year":"2017","journal-title":"J Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/acn3.411","article-title":"Dimethyl fumarate alters B-cell memory and cytokine production in MS patients","volume":"4","author":"Smith","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/bbrc.1997.6570","article-title":"Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells","volume":"234","author":"Vandermeeren","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"B129","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/sj.jid.5700996","article-title":"Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression","volume":"128","author":"Rubant","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/j.1600-0625.2011.01376.x","article-title":"Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions","volume":"20","author":"Wallbrecht","year":"2011","journal-title":"Exp Dermatol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/acn3.251","article-title":"Dimethyl fumarate inhibits integrin alpha4 expression in multiple sclerosis models","volume":"2","author":"Kihara","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.chom.2010.09.004","article-title":"Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif","volume":"8","author":"Neu","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B133","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1128\/JVI.00489-15","article-title":"The greater affinity of JC polyomavirus capsid for alpha2,6-linked lactoseries tetrasaccharide c than for other sialylated glycans is a major determinant of infectivity","volume":"89","author":"Stroh","year":"2015","journal-title":"J Virol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"13490","DOI":"10.1128\/JVI.02252-13","article-title":"5-HT2 receptors facilitate JC polyomavirus entry","volume":"87","author":"Assetta","year":"2013","journal-title":"J Virol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.ajpath.2015.04.003","article-title":"Human polyomavirus receptor distribution in brain parenchyma contrasts with receptor distribution in kidney and choroid plexus","volume":"185","author":"Haley","year":"2015","journal-title":"Am J Pathol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.virol.2007.02.018","article-title":"Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A","volume":"364","author":"Chapagain","year":"2007","journal-title":"Virology"},{"key":"B137","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ana.24192","article-title":"A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient","volume":"76","author":"Agnihotri","year":"2014","journal-title":"Ann Neurol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/13550280152537102","article-title":"A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region","volume":"7","author":"Jensen","year":"2001","journal-title":"J Neurovirol"},{"key":"B139","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/jvi.66.10.5726-5734.1992","article-title":"JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy","volume":"66","author":"White","year":"1992","journal-title":"J Virol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1099\/0022-1317-79-4-789","article-title":"Human polyomavirus JC control region variants in persistently infected CNS and kidney tissue","volume":"79","author":"Elsner","year":"1998","journal-title":"J Gen Virol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"9200","DOI":"10.1128\/JVI.00609-10","article-title":"JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy","volume":"84","author":"Tan","year":"2010","journal-title":"J Virol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.transci.2016.07.014","article-title":"Immunomodulatory effects of exosomes produced by virus-infected cells","volume":"55","author":"Petrik","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"B143","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","article-title":"Regulation of immune responses by extracellular vesicles","volume":"14","author":"Robbins","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fmicb.2016.01274","article-title":"Circulating MicroRNAs: potential and emerging biomarkers for diagnosis of human infectious diseases","volume":"7","author":"Verma","year":"2016","journal-title":"Front Microbiol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1743-422X-11-41","article-title":"Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects","volume":"11","author":"Lagatie","year":"2014","journal-title":"Virol J"},{"key":"B146","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1743-422X-11-158","article-title":"Viral miRNAs in plasma and urine divulge JC polyomavirus infection","volume":"11","author":"Lagatie","year":"2014","journal-title":"Virol J"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2015.01.019","article-title":"Expression of BKV and JCV encoded microRNA in human cerebrospinal fluid, plasma and urine","volume":"65","author":"Pietila","year":"2015","journal-title":"J Clin Virol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"9823","DOI":"10.1128\/JVI.01144-08","article-title":"Evolutionarily conserved function of a viral microRNA","volume":"82","author":"Seo","year":"2008","journal-title":"J Virol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chom.2011.01.008","article-title":"An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination","volume":"9","author":"Bauman","year":"2011","journal-title":"Cell Host Microbe"},{"key":"B150","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1089\/vim.2017.0039","article-title":"Association between BKPyV serotype I antibody level and natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Rossi","year":"2017","journal-title":"Viral Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1172\/JCI76629","article-title":"Human glial chimeric mice reveal astrocytic dependence of JC virus infection","volume":"124","author":"Kondo","year":"2014","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte-endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"B153","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/1531-8249(200001)47:1<18::AID-ANA6>3.0.CO;2-N","article-title":"Meningeal cells can communicate with astrocytes by calcium signaling","volume":"47","author":"Grafstein","year":"2000","journal-title":"Ann Neurol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF01206666","article-title":"Meningeal cells increase in vitro astrocytic gap junctional communication as measured by fluorescence recovery after laser photobleaching","volume":"18","author":"Anders","year":"1989","journal-title":"J Neurocytol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.cellsig.2015.09.012","article-title":"Gap junctional shuttling of miRNA \u2013 a novel pathway of intercellular gene regulation and its prospects in clinical application","volume":"27","author":"Lemcke","year":"2015","journal-title":"Cell Signal"},{"key":"B156","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fncel.2014.00122","article-title":"Regulation of gap junction channels by infectious agents and inflammation in the CNS","volume":"8","author":"Castellano","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1471-4159.2008.05405.x","article-title":"Glial connexins and gap junctions in CNS inflammation and disease","volume":"106","author":"Kielian","year":"2008","journal-title":"J Neurochem"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.bbrc.2010.03.111","article-title":"Astrocytes modulate the chemokine network in a pathogen-specific manner","volume":"394","author":"McKimmie","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B159","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fncel.2013.00058","article-title":"Imaging the microanatomy of astrocyte-T-cell interactions in immune-mediated inflammation","volume":"7","author":"Barcia","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"B160","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","article-title":"Balancing the immune response in the brain: IL-10 and its regulation","volume":"13","author":"Lobo-Silva","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B161","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/jvi.46.1.170-176.1983","article-title":"Nucleotide sequence of the region encompassing the JC virus origin of DNA replication","volume":"46","author":"Frisque","year":"1983","journal-title":"J Virol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.1128\/JVI.00542-09","article-title":"Regulation of gene expression in primate polyomaviruses","volume":"83","author":"White","year":"2009","journal-title":"J Virol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0042-6822(91)90136-Y","article-title":"Altered DNA binding and replication activities of JC virus T-antigen mutants","volume":"183","author":"Tavis","year":"1991","journal-title":"Virology"},{"key":"B164","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1128\/JVI.74.2.755-763.2000","article-title":"Glial cell-specific regulation of the JC virus early promoter by large T antigen","volume":"74","author":"Kim","year":"2000","journal-title":"J Virol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e14630","DOI":"10.1371\/journal.pone.0014630","article-title":"Regulation of human neurotropic JC virus replication by alternative splicing factor SF2\/ASF in glial cells","volume":"6","author":"Sariyer","year":"2011","journal-title":"PLoS One"},{"key":"B166","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1743-422X-10-147","article-title":"SF2\/ASF binding region within JC virus NCCR limits early gene transcription in glial cells","volume":"10","author":"Uleri","year":"2013","journal-title":"Virol J"},{"key":"B167","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12985-015-0426-x","article-title":"Molecular interplay between T-antigen and splicing factor, arginine\/serine-rich 1 (SRSF1) controls JC virus gene expression in glial cells","volume":"12","author":"Craigie","year":"2015","journal-title":"Virol J"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e0156819","DOI":"10.1371\/journal.pone.0156819","article-title":"Pur-alpha induces JCV gene expression and viral replication by suppressing SRSF1 in glial cells","volume":"11","author":"Sariyer","year":"2016","journal-title":"PLoS One"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e0129694","DOI":"10.1371\/journal.pone.0129694","article-title":"IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression","volume":"10","author":"De-Simone","year":"2015","journal-title":"PLoS One"},{"key":"B170","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s13365-016-0492-x","article-title":"JC polyomavirus expression and bell-shaped regulation of its SF2\/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab","volume":"23","author":"Uleri","year":"2017","journal-title":"J Neurovirol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B172","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1099\/vir.0.035832-0","article-title":"JC virus promoter\/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes","volume":"93","author":"Marshall","year":"2012","journal-title":"J Gen Virol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.virol.2007.05.016","article-title":"Microarray analysis of glial cells resistant to JCV infection suggests a correlation between viral infection and inflammatory cytokine gene expression","volume":"366","author":"Manley","year":"2007","journal-title":"Virology"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/nar\/21.8.1959","article-title":"The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS","volume":"21","author":"Ranganathan","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"12079","DOI":"10.1128\/JVI.01456-06","article-title":"NFAT4 is required for JC virus infection of glial cells","volume":"80","author":"Manley","year":"2006","journal-title":"J Virol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"8745","DOI":"10.1523\/JNEUROSCI.1002-07.2007","article-title":"Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals","volume":"27","author":"Fernandez","year":"2007","journal-title":"J Neurosci"},{"key":"B177","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.virol.2012.06.010","article-title":"Cooperative roles of NF-kappaB and NFAT4 in polyomavirus JC regulation at the KB control element","volume":"432","author":"Wollebo","year":"2012","journal-title":"Virology"},{"key":"B178","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1743-422X-10-264","article-title":"Epigenetic regulation of polyomavirus JC","volume":"10","author":"Wollebo","year":"2013","journal-title":"Virol J"},{"key":"B179","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12974-015-0393-6","article-title":"Fingolimod induces neuroprotective factors in human astrocytes","volume":"12","author":"Hoffmann","year":"2015","journal-title":"J Neuroinflammation"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1073\/pnas.1615413114","article-title":"Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation","volume":"114","author":"Rothhammer","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B181","doi-asserted-by":"publisher","first-page":"e81907","DOI":"10.1371\/journal.pone.0081907","article-title":"Fingolimod (FTY720) stimulates Ca(2+)\/calcineurin signaling in fission yeast","volume":"8","author":"Hagihara","year":"2013","journal-title":"PLoS One"},{"key":"B182","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.4049\/jimmunol.168.9.4781","article-title":"Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B\/p65 in human endothelial cells","volume":"168","author":"Loewe","year":"2002","journal-title":"J Immunol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jneuroim.2015.04.006","article-title":"DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner","volume":"283","author":"Gillard","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/acn3.414","article-title":"Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation","volume":"4","author":"Galloway","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2013.07.007","article-title":"Dimethyl fumarate regulates histone deacetylase expression in astrocytes","volume":"263","author":"Kalinin","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fcell.2016.00071","article-title":"Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair","volume":"4","author":"Domingues","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jns.2007.08.044","article-title":"Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders","volume":"267","author":"De Keyser","year":"2008","journal-title":"J Neurol Sci"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e0155897","DOI":"10.1371\/journal.pone.0155897","article-title":"JC polyomavirus abundance and distribution in progressive multifocal leukoencephalopathy (PML) brain tissue implicates myelin sheath in intracerebral dissemination of infection","volume":"11","author":"Wharton","year":"2016","journal-title":"PLoS One"},{"key":"B189","doi-asserted-by":"publisher","first-page":"10448","DOI":"10.1128\/JVI.00614-10","article-title":"Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate","volume":"84","author":"Gosert","year":"2010","journal-title":"J Virol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e1000368","DOI":"10.1371\/journal.pgen.1000368","article-title":"Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)","volume":"5","author":"Sunyaev","year":"2009","journal-title":"PLoS Genet"},{"key":"B191","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1099\/vir.0.037440-0","article-title":"JC virus granule cell neuronopathy is associated with VP1 C terminus mutants","volume":"93","author":"Dang","year":"2012","journal-title":"J Gen Virol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"e35793","DOI":"10.1371\/journal.pone.0035793","article-title":"JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant","volume":"7","author":"Dang","year":"2012","journal-title":"PLoS One"},{"key":"B194","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WCO.0000000000000201","article-title":"Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area","volume":"28","author":"Miskin","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J Infect Dis"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01335-16","article-title":"Deep-sequence identification and role in virus replication of a JC virus quasispecies in patients with progressive multifocal leukoencephalopathy","volume":"91","author":"Takahashi","year":"2017","journal-title":"J Virol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"306ra150","DOI":"10.1126\/scitranslmed.aac8691","article-title":"Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy","volume":"7","author":"Jelcic","year":"2015","journal-title":"Sci Transl Med"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00705-014-1988-4","article-title":"High-resolution melting analysis for mutation scanning in the non-coding control region of JC polyomavirus from patients with progressive multifocal leukoencephalopathy","volume":"159","author":"Nakamichi","year":"2014","journal-title":"Arch Virol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcv.2013.03.009","article-title":"Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants","volume":"57","author":"Ryschkewitsch","year":"2013","journal-title":"J Clin Virol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ana.22609","article-title":"Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci","volume":"70","author":"Patsopoulos","year":"2011","journal-title":"Ann Neurol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"B202","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/gene.2016.23","article-title":"GWAS analysis implicates NF-kappaB-mediated induction of inflammatory T cells in multiple sclerosis","volume":"17","author":"Hussman","year":"2016","journal-title":"Genes Immun"},{"key":"B203","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13059-017-1207-1","article-title":"The MHC locus and genetic susceptibility to autoimmune and infectious diseases","volume":"18","author":"Matzaraki","year":"2017","journal-title":"Genome Biol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/aje\/kwk118","article-title":"HLA-DR15 haplotype and multiple sclerosis: a HuGE review","volume":"165","author":"Schmidt","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog"},{"key":"B206","doi-asserted-by":"publisher","first-page":"948723","DOI":"10.1155\/2015\/948723","article-title":"The protective role of HLA-DRB1(*)13 in autoimmune diseases","volume":"2015","author":"Bettencourt","year":"2015","journal-title":"J Immunol Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1034\/j.1600-0404.2003.00165.x","article-title":"Promoter polymorphism of IL-10 and severity of multiple sclerosis","volume":"108","author":"Luomala","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1177\/1352458513490542","article-title":"Differential microRNA expression in blood in multiple sclerosis","volume":"19","author":"Sondergaard","year":"2013","journal-title":"Mult Scler"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.febslet.2011.05.029","article-title":"MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation","volume":"585","author":"Liu","year":"2011","journal-title":"FEBS Lett"},{"key":"B210","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/eji.201343734","article-title":"Differential post-transcriptional regulation of IL-10 by TLR2 and TLR4-activated macrophages","volume":"44","author":"Teixeira-Coelho","year":"2014","journal-title":"Eur J Immunol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molimm.2010.09.008","article-title":"Differential regulation of TLR4 expression in human B cells and monocytes","volume":"48","author":"Ganley-Leal","year":"2010","journal-title":"Mol Immunol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1128\/JVI.80.2.866-874.2006","article-title":"Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6","volume":"80","author":"Machida","year":"2006","journal-title":"J Virol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00705-015-2493-0","article-title":"Single-nucleotide polymorphism of toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients","volume":"160","author":"Sadik","year":"2015","journal-title":"Arch Virol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/cei.12578","article-title":"Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious diseases","volume":"180","author":"Skevaki","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","article-title":"Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis","volume":"131","author":"Sampaio","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B217","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/acn3.279","article-title":"Progressive multifocal leukoencephalopathy in an immunocompetent patient","volume":"3","author":"van der Kolk","year":"2016","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:34:08Z","timestamp":1693499648000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":217,"alternative-id":["10.3389\/fimmu.2018.00138"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00138","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"article-number":"138"}}